ICU Medical Inc. (NASDAQ:ICUI) – Analysts at Roth Capital increased their Q3 2016 earnings per share estimates for ICU Medical in a research note issued to investors on Thursday. Roth Capital analyst C. Lewis now anticipates that the brokerage will post earnings of $1.01 per share for the quarter, up from their previous estimate of $0.93. Roth Capital also issued estimates for ICU Medical’s Q4 2016 earnings at $0.95 EPS, FY2016 earnings at $3.90 EPS, Q3 2017 earnings at $1.08 EPS and FY2017 earnings at $4.21 EPS.
Several other equities research analysts also recently commented on the stock. Zacks Investment Research upgraded shares of ICU Medical from a “hold” rating to a “buy” rating and set a $141.00 price target for the company in a research report on Wednesday, September 21st. Piper Jaffray Cos. restated a “neutral” rating and issued a $119.00 price target (up previously from $115.00) on shares of ICU Medical in a research report on Thursday, August 11th.
Shares of ICU Medical (NASDAQ:ICUI) opened at 148.75 on Monday. The stock has a market capitalization of $2.40 billion, a PE ratio of 44.30 and a beta of 0.37. The stock’s 50 day moving average is $127.54 and its 200 day moving average is $113.26. ICU Medical has a 52 week low of $85.56 and a 52 week high of $152.67.
ICU Medical (NASDAQ:ICUI) last announced its quarterly earnings data on Monday, August 8th. The company reported $1.15 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $1.05 by $0.10. ICU Medical had a net margin of 14.94% and a return on equity of 10.33%. The company earned $96.70 million during the quarter, compared to analysts’ expectations of $89.66 million. During the same period in the previous year, the company earned $0.97 EPS. The business’s quarterly revenue was up 15.4% compared to the same quarter last year.
In other news, VP Steven Riggs sold 44,739 shares of the stock in a transaction on Tuesday, September 13th. The shares were sold at an average price of $121.78, for a total transaction of $5,448,315.42. Following the transaction, the vice president now owns 675 shares in the company, valued at approximately $82,201.50. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, Director Richard Md Sherman sold 1,500 shares of the stock in a transaction on Thursday, October 6th. The stock was sold at an average price of $140.60, for a total transaction of $210,900.00. Following the transaction, the director now owns 70,699 shares in the company, valued at approximately $9,940,279.40. The disclosure for this sale can be found here. 15.90% of the stock is currently owned by company insiders.
Several hedge funds and other institutional investors have recently made changes to their positions in ICUI. Eqis Capital Management Inc. raised its position in shares of ICU Medical by 86.3% in the third quarter. Eqis Capital Management Inc. now owns 4,675 shares of the company’s stock valued at $591,000 after buying an additional 2,166 shares during the period. Mason Street Advisors LLC acquired a new position in shares of ICU Medical during the second quarter valued at approximately $319,000. Royal Bank of Canada raised its position in shares of ICU Medical by 57.2% in the second quarter. Royal Bank of Canada now owns 207,226 shares of the company’s stock valued at $23,365,000 after buying an additional 75,396 shares during the period. Schwab Charles Investment Management Inc. raised its position in shares of ICU Medical by 4.3% in the second quarter. Schwab Charles Investment Management Inc. now owns 48,889 shares of the company’s stock valued at $5,513,000 after buying an additional 2,004 shares during the period. Finally, Stifel Financial Corp raised its position in shares of ICU Medical by 10.9% in the second quarter. Stifel Financial Corp now owns 67,649 shares of the company’s stock valued at $7,627,000 after buying an additional 6,656 shares during the period. Institutional investors own 89.52% of the company’s stock.
ICU Medical Company Profile
ICU Medical, Inc is engaged in the development, manufacturing and sales of medical devices used in infusion therapy, oncology and critical care applications. The Company’s product line includes needlefree connection devices, closed system transfer devices (CSTD), needlefree closed blood sampling systems, disposable pressure transducer systems and hemodynamic monitoring systems.
Receive News & Ratings for ICU Medical Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ICU Medical Inc. and related companies with MarketBeat.com's FREE daily email newsletter.